KalVista Pharmaceuticals (KALV) Cash from Investing Activities (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Cash from Investing Activities of $21.3 million in Q3 2025, up 738.85% quarter-over-quarter from -$3.3 million in Q2 2025, and down 42.79% year-over-year from $37.2 million in Q3 2024.
KalVista Pharmaceuticals' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at $21.3 million for Q3 2025.
- In Q3 2025, Cash from Investing Activities fell 42.79% year-over-year to $21.3 million; the TTM figure through Jul 2025 stood at $103.8 million (up 254.49% YoY), while the FY2025 annual figure was $91.0 million, up 207.44% from the prior year.
- Cash from Investing Activities came in at $21.3 million for Q3 2025 at KalVista Pharmaceuticals, up from -$3.3 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $48.7 million in Q4 2024 to a low of -$166.5 million in Q2 2021.
- A 5-year average of -$2.3 million and a median of $13.9 million in 2021 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities soared 176.93% in 2021 and slumped 1931.98% in 2024, its largest moves.
- KalVista Pharmaceuticals' Cash from Investing Activities stood at $17.6 million in 2021, then climbed by 13.91% to $20.1 million in 2022, then jumped by 42.08% to $28.6 million in 2023, then jumped by 70.45% to $48.7 million in 2024, then plunged by 56.32% to $21.3 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $21.3 million, -$3.3 million, and $48.7 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 21.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 21.26 Mn |
| Jul 31, 2025 | 21.26 Mn |
| Apr 30, 2025 | -3.33 Mn |
| Apr 30, 2025 | -3.33 Mn |
| Oct 31, 2024 | 48.67 Mn |
| Oct 31, 2024 | 48.67 Mn |
| Jul 31, 2024 | 37.16 Mn |
| Jul 31, 2024 | 37.16 Mn |
| Apr 30, 2024 | -126.19 Mn |
| Apr 30, 2024 | -126.19 Mn |
| Jan 31, 2024 | -6.70 Mn |
| Jan 31, 2024 | -6.70 Mn |
| Oct 31, 2023 | 28.56 Mn |
| Oct 31, 2023 | 28.56 Mn |
| Jul 31, 2023 | 19.61 Mn |
| Jul 31, 2023 | 19.61 Mn |
| Apr 30, 2023 | -6.21 Mn |
| Apr 30, 2023 | -6.21 Mn |
| Jan 31, 2023 | -2.52 Mn |
| Jan 31, 2023 | -2.52 Mn |
| Oct 31, 2022 | 20.10 Mn |
| Oct 31, 2022 | 20.10 Mn |
| Jul 31, 2022 | 30.04 Mn |
| Jul 31, 2022 | 30.04 Mn |
| Apr 30, 2022 | 12.43 Mn |
| Apr 30, 2022 | 12.43 Mn |
| Jan 31, 2022 | 12.90 Mn |
| Jan 31, 2022 | 12.90 Mn |
| Oct 31, 2021 | 17.64 Mn |
| Oct 31, 2021 | 17.64 Mn |
| Jul 31, 2021 | 14.88 Mn |
| Jul 31, 2021 | 14.88 Mn |
| Apr 30, 2021 | -166.48 Mn |
| Apr 30, 2021 | -166.48 Mn |
| Jan 31, 2021 | 6.95 Mn |
| Jan 31, 2021 | 6.95 Mn |
| Oct 31, 2020 | 6.37 Mn |
| Oct 31, 2020 | 6.37 Mn |
| Jul 31, 2020 | 5.51 Mn |
| Jul 31, 2020 | 5.51 Mn |
| Apr 30, 2020 | 10.03 Mn |
| Apr 30, 2020 | 10.03 Mn |
| Jan 31, 2020 | 9.77 Mn |
| Jan 31, 2020 | 9.77 Mn |
| Oct 31, 2019 | -1.51 Mn |
| Oct 31, 2019 | -1.51 Mn |
| Jul 31, 2019 | -1.53 Mn |
| Jul 31, 2019 | -1.53 Mn |
| Apr 30, 2019 | -14.05 Mn |
| Apr 30, 2019 | -14.05 Mn |
| Jan 31, 2019 | -54.59 Mn |
| Jan 31, 2019 | -54.59 Mn |
| Oct 31, 2018 | -221,000.00 |
| Oct 31, 2018 | -221,000.00 |
| Jul 31, 2018 | -565,000.00 |
| Jul 31, 2018 | -565,000.00 |
| Apr 30, 2018 | -1.08 Mn |
| Apr 30, 2018 | -1.08 Mn |
| Jan 31, 2018 | -182,000.00 |
| Jan 31, 2018 | -182,000.00 |
| Oct 31, 2017 | -51,000.00 |
| Oct 31, 2017 | -51,000.00 |
| Jul 31, 2017 | -110,000.00 |
| Jul 31, 2017 | -110,000.00 |
| Apr 30, 2017 | -7,000.00 |
| Apr 30, 2017 | -7,000.00 |
| Jan 31, 2017 | 34.13 Mn |
| Jan 31, 2017 | 34.13 Mn |
| Oct 31, 2016 | -18,000.00 |
| Oct 31, 2016 | -18,000.00 |
| Jul 31, 2016 | -43,000.00 |
| Jul 31, 2016 | -43,000.00 |
| Mar 31, 2016 | -184,000.00 |
| Mar 31, 2016 | -184,000.00 |
| Dec 31, 2015 | -1.09 Mn |
| Dec 31, 2015 | -1.09 Mn |
| Sep 30, 2015 | -21,000.00 |
| Sep 30, 2015 | -21,000.00 |
| Jun 30, 2015 | -79,000.00 |
| Jun 30, 2015 | -79,000.00 |
| Mar 31, 2015 | -180,000.00 |
| Mar 31, 2015 | -180,000.00 |
| Sep 30, 2014 | -7,000.00 |
| Sep 30, 2014 | -7,000.00 |
| Jun 30, 2014 | -75,000.00 |
| Jun 30, 2014 | -75,000.00 |
| Mar 31, 2014 | -1,000.00 |
| Mar 31, 2014 | -1,000.00 |